Načítá se...
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
BACKGROUND: Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is being investigated as an adjunctive hemostatic treatment for bleeding refractory...
Uloženo v:
Hlavní autoři: | , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BioMed Central
2007
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2206502/ https://ncbi.nlm.nih.gov/pubmed/17686152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc6092 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|